9.1 C
London
HomeAnalysis

Analysis

Davos 2026: The Last Chance to Save the New World Order

Davos 2026 emerges, paradoxically, as a decisive rendezvous precisely when the global order, once thought immutable, is visibly crumbling. In the heart of the Swiss Alps, under the modest theme “A Spirit of Dialogue,” over 130 countries, political leaders, and thousands of business executives...

NFG SA Capital Intelligence: Strategic Investment in a Changing Global Market

Understanding NFG SA Capital Intelligence in Today’s Financial Landscape NFG SA capital intelligence lies at the core of a strategic investment philosophy reshaping how capital is managed in global markets. Headquartered in Geneva, NFG SA blends Swiss regulatory rigour with an expansive international footprint. Its...

South Korea’s Tech Pivot: Sovereign AI in the Shadow of Superpowers

South Korea, long wedged between Washington and Beijing in the multipolar contest for technological primacy, is now deliberately pitching its burgeoning AI ecosystem as a third path — a sovereign alternative that neither bows to Silicon Valley’s behemoths nor to the sprawling data leviathans...

Top of Most Profitable Assets in 2025: Full Review, Weak Spots, and Forecasts for 2026

The year 2025 has been marked by major divergences in asset performance across global markets. The Top 50 most profitable assets in 2025 reveal an increasingly polarised financial landscape, dominated by precious metals, Big Tech, and digital assets. Meanwhile, traditional sectors and low-yield investments...

Envirotech Vehicles AI Pivot Gains Clarity Amid Strategic Engagement with AZIO AI

AZIO AI has provided further detail on its ongoing strategic discussions with Envirotech Vehicles, Inc. (NASDAQ: EVTV), reinforcing its commitment to a disciplined transaction process. These talks centre on facilitating the Envirotech Vehicles AI pivot, which could see EVTV repositioned within the rapidly expanding...

Samsung Biologics U.S. Expansion Accelerates with Strategic Acquisition of GSK’s Rockville Facility

Samsung Biologics U.S. expansion is gaining momentum through a landmark acquisition of Human Genome Sciences from GSK, a move that marks its first biomanufacturing presence in the United States. In a deal valued at USD 280 million, Samsung Biologics America, a wholly owned subsidiary of...